-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 F+PxHKcKe4v5ohQn0ttJ+h8JW9LIH2zArEwq6UCsksN/dUws+eWfbeCDvVaJm45C
 tsJxF3dwg76EAd+yU/Pw1g==

<SEC-DOCUMENT>0000950123-10-113504.txt : 20101214
<SEC-HEADER>0000950123-10-113504.hdr.sgml : 20101214
<ACCEPTANCE-DATETIME>20101214165037
ACCESSION NUMBER:		0000950123-10-113504
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20101210
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101214
DATE AS OF CHANGE:		20101214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		101251082

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c09737e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">
<DIV style="font-size: 10pt">
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 1pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): December 10, 2010</B>


<P style="font-size: 24pt" align="center"><B>CYCLACEL PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-50626</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>91-1707622</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>200 Connell Drive, Suite
1500<BR>
Berkeley Heights, NJ <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07922</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 517-7330</B>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="30%">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="border-bottom: black 1pt solid; margin-top: 10pt; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">

 <TR style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt" valign="top">
  <TD width="3%" nowrap align="left"><B>Item&nbsp;5.02</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.</B> </TD>
</TR>
</TABLE>

<P style="font-size: 10pt" align="justify">(e)&nbsp;<U>Change in Control Agreement</U>

<P style="text-indent: 4%; font-size: 10pt" align="justify">On
December&nbsp;10, 2010, the board of directors of Cyclacel Pharmaceuticals,
Inc. (the &#8220;<B>Company</B>&#8221;), at the recommendation of the
Company&#8217;s Compensation and Organization Development Committee (the
&#8220;<B>Committee</B>&#8221;), approved the Change in Control Agreement (the
&#8220;<B>CIC Agreements</B>&#8221;) to be entered into by and between the
Company and Dr.&nbsp;Judy Chiao, the Company&#8217;s Vice President, Clinical
Development and Regulatory Affairs.

<P style="text-indent: 4%; font-size: 10pt" align="justify">In the event of a
Change in Control (as defined below) of the Company, and Dr.&nbsp;Chiao&#8217;s
employment with the continuing or surviving company (the &#8220;<B>Controlling
Company</B>&#8221;) is terminated (including if Dr.&nbsp;Chiao voluntarily
terminates her employment for Good Reason, as defined below) at any time within
six months following the effective date of a Change in Control, unless such
termination is For Cause, death, disability or Dr.&nbsp;Chiao voluntarily
leaves without Good Reason (as each such term is defined below), Dr.&nbsp;Chiao
will be entitled to receive the following benefits from the Controlling Company
in lieu of any further salary and bonus payments to Dr.&nbsp;Chiao for certain
periods subsequent to the date of termination in consideration for
Dr.&nbsp;Chiao&#8217;s execution and delivery of a general release in favor of
the Controlling Company:

<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">payment by the Controlling Company of a lump
sum severance payment equal to Dr.&nbsp;Chiao&#8217;s annual salary for a
period of twelve months from the date of termination;</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">payment by the Controlling Company of all
unpaid, accrued vacation through the date of termination;</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">all options to purchase shares of the
Company&#8217;s common stock held by Dr.&nbsp;Chiao shall be vested and
exercisable for twelve months following the effective date of the Change in
Control; and</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">the Controlling Company shall arrange coverage
for Dr.&nbsp;Chiao and her dependents, as the case may be, under medical care
and life insurance benefit plans substantially similar to those which
Dr.&nbsp;Chiao and her dependents were entitled immediately prior to the
effective date of the Change in Control for a period of up to twelve months
after the effective date of the Change in Control, subject to certain
exceptions as set forth in more detail in the CIC Agreement.</DIV>
</TD>
 </TR>

</TABLE>


<P style="text-indent: 4%; font-size: 10pt" align="justify">Under the terms of
the CIC Agreement, a &#8220;<B>Change in Control</B>&#8221; shall be deemed to
have taken place in the event:

<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">any consolidation or merger of the Company is
consummated in which Company is not the continuing or surviving corporation or
pursuant to any transaction in which shares of the Company&#8217;s capital
stock are converted into cash, securities or other property, or any sale,
lease, exchange or other transfer in one transaction or a series of
transactions contemplated or arranged by any party as a single plan of all or
substantially all of the assets of the Company, or the approval of a plan of
complete liquidation or dissolution of the Company adopted by the stockholders
of the Company;</DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">1

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">



<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">

 <TR style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD><DIV style="text-align: justify">any person (as such term is used in
Sections&nbsp;13(d<U>)</U> and 14(d)(2) of the Securities Exchange Act of 1934,
as amended (the &#8220;<B>Exchange Act</B>&#8221;)) shall, after the date of
the CIC Agreement, become the beneficial owner (as defined in Rules&nbsp;13d-3
and 13d-5 under the Exchange Act), directly or indirectly, of
securities of the Company representing 35% or more of the voting power of all
then outstanding securities of the Company having the right under ordinary
circumstances to vote in an election of the board of directors (the
&#8220;<B>Board</B>&#8221;); or </DIV></TD>
</TR>

</TABLE>




<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">individuals who, at the date of the CIC
Agreement, constitute the entire Board and any new directors whose election by
the Board, or whose nomination for election by the Company&#8217;s
stockholders, shall have been approved by a vote of at least a majority of the
directors then in office who either were directors as of such date or whose
election or nomination for election shall have been so approved shall cease for
any reason to constitute a majority of the members of the Board.</DIV>
</TD>
 </TR>

</TABLE>


<P style="text-indent: 4%; font-size: 10pt"
align="justify">Dr.&nbsp;Chiao&#8217;s employment shall have been terminated
&#8220;<B>For Cause</B>&#8221; if the Controlling Company shall have terminated
Dr. Chiao as a result of: (A)&nbsp;improper conduct, consisting of any willful
act or omission with the intent of obtaining, to the material detriment of the
Controlling Company, any benefit to which Dr.&nbsp;Chiao would not otherwise be
entitled; (B) gross negligence, consisting of wanton and reckless acts or
omissions in the performance of Dr.&nbsp;Chiao&#8217;s duties to the material
detriment of the Controlling Company; (C)&nbsp;addiction to drugs or chronic
alcoholism; or (D)&nbsp;any conviction of, or plea of <I>nolo contendere
</I>to, a crime (other than a traffic violation) under the laws of the United
States or any political subdivision thereof, subject to certain requirements,
as set forth in more detail in the CIC Agreement.

<P style="text-indent: 4%; font-size: 10pt" align="justify">Dr.&nbsp;Chiao
shall be deemed to have terminated her employment for &#8220;<B>Good
Reason</B>&#8221; if the Controlling Company (A) materially reduces
Dr.&nbsp;Chiao&#8217;s duties, responsibilities or authority commensurate with
his or her position immediately prior to the effective date of the Change in
Control; (B)&nbsp;reduces Dr.&nbsp;Chiao&#8217;s base salary in effect
immediately prior to the effective date of the Change of Control;
(C)&nbsp;requires Dr.&nbsp;Chiao to relocate to another office more than 50
miles of her office location immediately prior to the effective date of the
Change of Control, subject to certain exceptions, as more fully set forth in
detail in the CIC Agreement; or (D)&nbsp;fails to offer Dr.&nbsp;Chiao all
material benefits offered to all other employees of the Controlling Company,
and the Controlling Company fails to correct or cure the acts giving rise to
the termination of Dr.&nbsp;Chiao&#8217;s employment for &#8220;Good
Reason,&#8221; after receipt of Dr.&nbsp;Chiao&#8217;s notice of such acts.

<P style="text-indent: 4%; font-size: 10pt" align="justify">The foregoing
description of the CIC Agreement is qualified in its entirety by reference to
the provisions of the CIC Agreement, the form of which is attached to this
Current Report on Form 8-K as Exhibit&nbsp;10.1.

<P style="font-size: 10pt" align="justify"><U>Employment Agreement
Renewals</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<P style="text-indent: 4%; font-size: 10pt" align="justify">On
December&nbsp;10, 2010, the board of directors of the Company also approved, at
the recommendation of the Committee, the renewal of the employment agreements
(each, an &#8220;<B>Employment Agreement</B>&#8221;) of Spiro Rombotis, the
President and Chief Executive Officer of the Company, and Paul McBarron, the
Executive Vice President, Finance, Chief Financial Officer and Chief Operating
Officer of the Company.

<P style="text-indent: 4%; font-size: 10pt" align="justify">The terms of
Mr.&nbsp;Rombotis&#8217;s Employment Agreement, which were previously disclosed
under cover of a Current Report on Form 8-K filed on March&nbsp;21, 2008,
remain unchanged, except: (i)&nbsp;the term has been extended for another three
years, to December&nbsp;31, 2013; (ii)&nbsp;his base salary has been increased
by 3% to $490,383; and (iii)&nbsp;certain technical changes were made to comply
with final regulations issued under Section&nbsp;409A of the Internal Revenue
Code of 1986, as amended (&#8220;<B>Section&nbsp;409A</B>&#8221;) and similar
regulations.

<P style="font-size: 10pt" align="center">2

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="text-indent: 4%; font-size: 10pt" align="justify">The terms of
Mr.&nbsp;McBarron&#8217;s Employment Agreement, which were previously disclosed
under cover of a Current Report on Form 8-K filed on April&nbsp;2, 2008, remain
unchanged, except: (i)&nbsp;the term has been extended for another three years,
to December&nbsp;31, 2013; and (ii)&nbsp;his base salary has been increased by
3% to &#163;192,955.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;9.01 Financial
Statements and Exhibits.</B>

<P style="text-indent: 4%; font-size: 10pt"
align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)&nbsp; Exhibits.

<DIV align="center">
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left"><B>Exhibit<BR>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD valign="bottom" align="left"><BR>
<B>Description</B></TD>
 </TR>


<TR><TD colspan="3">&nbsp;</TD></TR>

<TR valign="top">
<TD align="justify">10.1</TD>
<TD>&nbsp;</TD>
<TD align="justify">Form of Change in Control Agreement by and between Cyclacel
Pharmaceuticals, Inc. and Dr.&nbsp;Judy Chiao </TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P style="font-size: 10pt" align="center">3

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="text-indent: 4%; font-size: 10pt" align="justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" colspan="2"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD>
</TR>

<TR><TD colspan="3">&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">By: </TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">/s/ Paul McBarron</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Name: Paul McBarron<BR>Title: Executive Vice
President&#8212;Finance,<BR>
Chief Financial Officer and <BR>
Chief Operating Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>



<P style="font-size: 10pt" align="justify">Date: December&nbsp;14, 2010


<P style="font-size: 10pt" align="center">4

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">5
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>c09737exv10w1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<P align="right" style="font-size: 10pt"><B>Exhibit 10.1</B>

<P align="center" style="font-size: 10pt"><B>CHANGE IN CONTROL AGREEMENT</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">This Change in Control Agreement is dated as of December <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2010 (this &#147;<B>Agreement</B>&#148;), between Cyclacel
Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and Dr.&nbsp;Judy Chiao.


<P align="left" style="font-size: 10pt; text-indent: 4%">In the event of a Change in Control (as defined in <U>Section&nbsp;3</U>) of the Company, and your employment with the
continuing or surviving company (the &#147;<B>Controlling Company</B>&#148;) is terminated (including if you voluntarily terminate your
employment for Good Reason, as defined in <U>Section&nbsp;3</U>) at any time within six (6)&nbsp;months following the effective
date of a Change in Control, unless such termination is For Cause, death, disability or you voluntarily leave without
Good Reason (as each such term is defined in <U>Section&nbsp;3</U>), you will be entitled to receive the benefits described
below.


<P align="left" style="font-size: 10pt; text-indent: 4%">1.&nbsp;<U><B>Continued Benefits</B></U>. In lieu of any further salary and bonus payments to you for periods subsequent to
the date of termination, provided you execute and deliver to the Controlling Company a general release of any legal
claims that you may have against the Controlling Company in the form required by the Controlling Company (the
&#147;Release&#148;) and the Release is effective non-revocable before the date that is the sixtieth (60<SUP style="font-size: 85%; vertical-align: text-top">th</sup>) day
following the date of termination, you shall be entitled to the following benefits from the Controlling Company:


<P align="left" style="font-size: 10pt; text-indent: 8%">(a)&nbsp;payment by the Controlling Company of a lump sum severance payment, payable on the sixtieth (60<SUP style="font-size: 85%; vertical-align: text-top">th</sup>)
day following the date of termination, equal to your annual salary for a period of twelve (12)&nbsp;months from the date of
termination;


<P align="left" style="font-size: 10pt; text-indent: 8%">(b)&nbsp;payment by the Controlling Company of all unpaid, accrued vacation through the date of termination, payable on
the sixtieth (60<SUP style="font-size: 85%; vertical-align: text-top">th</sup>) day following the date of termination;


<P align="left" style="font-size: 10pt; text-indent: 8%">(c)&nbsp;all options to purchase shares of the Company&#146;s common stock held by you shall be vested and be exercisable
for a period of twelve (12)&nbsp;months following the effective date of the Change in Control; and


<P align="left" style="font-size: 10pt; text-indent: 8%">(d)&nbsp;the Controlling Company shall arrange coverage for you and your dependents, as the case may be, under medical
care and life insurance benefit plans substantially similar to those which you and your dependents were entitled
immediately prior to the effective date of the Change in Control for a period of up to twelve (12)&nbsp;months after the
effective date of the Change in Control; <I>provided, however</I>, that the Controlling Company&#146;s obligation to provide such
coverage shall be terminated if you obtain substitute coverage from another employer at any time during the
continuation period. You shall be obligated to notify the Controlling Company of any such substitute coverage and the
date of commencement thereof promptly upon obtaining any such coverage.


<P align="left" style="font-size: 10pt; text-indent: 4%">2.&nbsp;<U><B>Compliance with Section&nbsp;409A</B></U><B>.</B>


<P align="left" style="font-size: 10pt; text-indent: 8%">(a)&nbsp;The benefits set forth in Sections 1(a) and (b)&nbsp;are intended to be exempt from Section&nbsp;409A of the Internal
Revenue Code (the &#147;Code&#148;) as a short term deferral pursuant to Treas. Reg. &#167;1.409A-1(b)(4). The benefit set forth in
Section 1(c) is intended to be exempt from Section&nbsp;409A of the Code as a stock option pursuant to Treas. Reg.
&#167;1.409A-1(b)(5)(ii) or a nonstatutory stock option not providing for the deferral of compensation pursuant to Treas.
Reg. &#167;1.409A-1(b)(5)(i)(A). Notwithstanding the foregoing, if any of the benefits set forth in this Agreement are
&#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, any termination of employment triggering payment
of such benefits must constitute a &#147;separation from service&#148; under Section&nbsp;409A of the Code before distribution of such
benefits can commence. If at the time of your &#147;separation of service&#148;, you are a &#147;specified employee&#148; as defined in
Section&nbsp;409A(a)(2)(B)(i) of the Code, any benefits that constitute non-qualified deferred compensation under Section
409A of the Code shall be delayed until the first business day that is more than six months after your &#147;separation from
service&#148; from the Controlling Company became effective. To the extent that the termination of your employment does not
constitute a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code (as the result of further services that
are reasonably anticipated to be provided by you to the Controlling Company at the time your employment terminates),
any benefits that constitute deferred compensation under Section&nbsp;409A of the Code shall be further delayed until the
first business day that is more than six months after the date of a subsequent event constituting a separation of
service under Section&nbsp;409A(a)(2)(A)(i) of the Code. For purposes of clarification, this paragraph shall not cause any
forfeiture of benefits on your part, but shall only act as a delay until such time as a &#147;separation from service&#148;
occurs.

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<P align="left" style="font-size: 10pt; text-indent: 8%">(b)&nbsp;It is intended that each installment of the payments and benefits provided under this Agreement shall be
treated as a separate &#147;payment&#148; for purposes of Section&nbsp;409A of the Code. Neither the Controlling Company nor you
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent
specifically permitted or required by Section&nbsp;409A of the Code.


<P align="left" style="font-size: 10pt; text-indent: 8%">(c)&nbsp;Notwithstanding any other provision of this Agreement to the contrary, the Agreement shall be interpreted and
at all times administered in a manner that avoids the inclusion of compensation in income under Section&nbsp;409A(a)(1) of
the Code. Any provision inconsistent with Section&nbsp;409A of the Code will be read out of the Agreement. For purposes of
clarification, this <U>Section&nbsp;2(c)</U> shall be a rule of construction and interpretation, and nothing in this
<U>Section&nbsp;2(c)</U> shall cause a forfeiture of benefits on your part.


<P align="left" style="font-size: 10pt; text-indent: 4%">3.&nbsp;<U><B>Definitions</B></U>. The following terms have the following meanings:


<P align="left" style="font-size: 10pt; text-indent: 8%">(a)&nbsp;<B>Change in Control. </B>A &#147;Change in Control&#148; shall be deemed to have taken place if:


<P align="left" style="font-size: 10pt; text-indent: 12%">(i)&nbsp;there shall be consummated any consolidation or merger of the Company in which Company is not the continuing
or surviving corporation or pursuant to any transaction in which shares of the Company&#146;s capital stock are converted
into cash, securities or other property, or any sale, lease, exchange or other transfer in one transaction or a series
of transactions contemplated or arranged by any party as a single plan of all or substantially all of the assets of the
Company, or the approval of a plan of complete liquidation or dissolution of the Company adopted by the stockholders of
the Company; or


<P align="left" style="font-size: 10pt; text-indent: 12%">(ii)&nbsp;any person (as such term is used in Sections&nbsp;13(d<U>)</U> and 14(d)(2) of the Securities Exchange Act of
1934, as amended (the &#147;<B>Exchange Act</B>&#148;)) shall after the date hereof become the beneficial owner (as defined in Rules
13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of securities of the Company representing 35% or more
of the voting power of all then outstanding securities of the Company having the right under ordinary circumstances to
vote in an election of the board of directors (the &#147;<B>Board</B>&#148;) (including, without limitation, any securities of the
Company that any such person has the right to acquire pursuant to any agreement, or upon exercise of conversion rights,
warrants or options, or otherwise, shall be deemed beneficially owned by such person); or


<P align="left" style="font-size: 10pt; text-indent: 12%">(iii)&nbsp;individuals who at the date hereof constitute the entire Board and any new directors whose election by the
Board, or whose nomination for election by the Company&#146;s stockholders, shall have been approved by a vote of at least a
majority of the directors then in office who either were directors at the date hereof or whose election or nomination
for election shall have been so approved shall cease for any reason to constitute a majority of the members of the
Board.


<P align="left" style="font-size: 10pt; text-indent: 8%">(b)&nbsp;<B>For Cause</B>. Your employment shall be deemed to have been terminated &#147;For Cause&#148; if the Controlling Company
shall have terminated you as a result of any of the following: (A)&nbsp;improper conduct, consisting of any willful act or
omission with the intent of obtaining, to the material detriment of the Controlling Company, any benefit to which you
would not otherwise be entitled; (B)&nbsp;gross negligence, consisting of wanton and reckless acts or omissions in the
performance of your duties to the material detriment of the Controlling Company; (C)&nbsp;addiction to drugs or chronic
alcoholism; or (D)&nbsp;any conviction of, or plea of <I>nolo contendere </I>to, a crime (other than a traffic violation) under the
laws of the United States or any political subdivision thereof provided that you receive a copy of a resolution duly
adopted by a two-thirds majority affirmative vote of the membership of the board of directors of the Controlling
Company, at a meeting thereof called and held for such purpose, after you have been given reasonable notice of such
meeting and have been given an opportunity, together with your counsel, to be heard by the board of directors of the
Controlling Company, finding that in the good faith opinion of the board of directors of the Controlling Company you
were guilty of the conduct set forth and specifying the particulars thereof in detail.

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<P align="left" style="font-size: 10pt; text-indent: 8%">(c)&nbsp;<B>Good Reason</B>. Your employment shall be deemed as having been terminated by you for &#147;Good Reason&#148; if (i)&nbsp;the
Controlling Company (A)&nbsp;materially reduces your duties, responsibilities or authority commensurate with your position
immediately prior to the effective date of the Change in Control; (B)&nbsp;reduces your base salary in effect immediately
prior to the effective date of the Change of Control; (C)&nbsp;requires you to relocate to another office more than fifty
(50)&nbsp;miles of your office location immediately prior to the effective date of the Change of Control (except for
required travel related to your position to an extent substantially consistent with your business travel obligations
immediately prior to the effective date of the Change in Control); or (D)&nbsp;fails to offer you all material benefits
offered to all other employees of the Controlling Company; (ii)&nbsp;within ninety (90)&nbsp;days of the first occurrence of the
Controlling Company&#146;s acts giving rise to the termination of your employment for &#147;Good Reason&#148;, you notify the
Controlling Company in writing of those acts; and (iii)&nbsp;within thirty (30)&nbsp;days of receiving your written notice of
termination, the Controlling Company fails to fully correct or cure the acts giving rise to the termination of your
employment for &#147;Good Reason.&#148; For purposes of clarity, if the Controlling Company fails to correct or cure the acts
giving rise to the termination of your employment for &#147;Good Reason&#148;, the termination of your employment shall become
effective on the thirty-first day following the day on which the Controlling Company receives your written notice under
this Section.


<P align="left" style="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Spiro Rombotis, President and CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dr. Judy Chiao</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
